Barcelona, April 1th, 2019. iVascular specialized company in developing high quality vascular devices, is committed with the expansion of knowledge of young specialists in international reference centers through training grants. Therefore, the company has launched the iVascular Grant program. The program has been developed in association with the Endovascular Foundation, that in accordance with […]
Barcelona, February 12th, 2019. – Navitian, iVascular´s new coronary microcatheter receives the CE mark approval. iVascular is pleased to announce the release of Navitian, it’s a new Coronary Microcatheter, which has obtained the CE mark approval to: Facilitate, guide and support a guidewire while accessing to the coronary system, the exchange of guidewire and injection […]
Barcelona, November 14th of 2018.- iVascular S.L.U. has announced the completion of enrollment of patients in its T.I.N.T.I.N. (Treatment with the LumINor DCB and The IvolutioN self-expanding stent) study. The effectiveness of drug coated balloons (DCB) to inhibit restenosis in symptomatic superficial femoral artery (SFA) lesions, has been proven in many studies. However, the longer […]
iVascular acquires 10% of the shares of the American company NaviGate Cardiac Structures, Inc. for 10 million dollars.
Sant Vicenç dels Horts (Barcelona), October 18th of 2018.- Today, the collaboration agreement between iVascular and NaviGate Cardiac Structures, Inc (NCSI) has been formalized, under which iVascular acquires 10% of shares of NCSI for 10 million dollars. With this purchase, iVascular becomes part of the Board of Directors of the American company. The mentioned agreement […]
iVascular reveals 24 months outcomes of Anchor trial and presents outcomes of two major RCT at TCT 2018.
San Diego, September 24th, 2018 – iVascular reveals 24 months outcomes of Anchor trial and presents outcomes of two major RCT at TCT 2018. iVascular reveals 24 months outcomes of ANCHOR Trial, evaluating the safety and efficacy of Angiolite DES, at TCT 2018. The presentation was made by Dr. Rishi Puri, one of the PI […]
Lisbon, September 23rd, 2018. iVascular demonstrates benefits of leading products at CIRSE 20. 18The 12-month results from the full clinical cohort of the EFFPAC randomized controlled trial (RCT), were presented by Prof.Ulf Teichgräber (Jena University, Germany) at CIRSE 2018. Main objective of EFFPAC RCT was to assess the effectiveness of Luminor drug coated balloon (DCB) vs. […]
Paris, May 24th, 2018 – ANGIOLITE Trial 12-month results revealed at Euro PCR 2018 ANGIOLITE Trial 12-month results were presented for the first time at Euro PCR by Dr. J. Moreu Burgos at the “Clinical outcomes with new DES” session. The randomized prospective multicentric controlled trial enrolled 223 patients and had the objective of demonstrating […]
2 Major Randomized Controlled Trials demonstrating benefits of leading iVascular products have been presented at Euro PCR 2018.
Paris, May 24th, 2018 – 2 Major Randomized Controlled Trials demonstrating benefits of leading iVascular products have been presented at Euro PCR 2018. Dr Moreu Burgos and Prof Ulf Teichgraber have shared the latest 12-month results of ANGIOLITE and EFFPAC RCTs in Paris, during the “Clinical outcomes with new DES” and “Hotline Peripheral and Stroke […]
iVascular will attend Euro PCR 2018 in Paris from May 22nd to 25th. We are looking forward to meeting you on our booth (F12) to learn more about the company innovations and proprietary technology. The latest clinical trials updates will be presented during the following scientific sessions. Thursday 24th of May 2018 at 2:45pm […]
London, April 25th, 2018 – EFFPAC RCT 12-month outstanding results with Luminor DCB have been revealed at CX Symposium 2018. The 12-month results from the full clinical cohort of the EFFPAC randomized controlled trial (RCT), were presented for the first time at CX Symposium 2018 at the DCB session on April 24th. Main objective was […]
Barcelona, March 8th, 2018 – EFFPAC-RCT 12-month results will be presented for the first time on April 24th at CX Symposium 2018 The 12-month results from the full clinical cohort of the EFFPAC randomized control trial (RCT), comparing the Luminor DCB (iVascular) to POBA, are going to be presented for the first time at Charing […]
Barcelona, February 14th, 2018 – iVascular Luminor DCB proves to be the best! The EFFPAC 6-month results have been presented by Prof. Dierk Scheinert (Park-Krankenhaus Leipzig, Germany) at the opening of the LINC 2018 main session dedicated to latest results with new technologies for femoropopliteal obstructions. EFFPAC is a Randomized Controlled Study comparing the Luminor […]